Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives.
Matheus Sewastjanow-SilvaKohei YamashitaErnesto Rosa VicentiniMeita HirschmannMelissa Pool PizziAllison Michelle TrailRebecca E WatersJane E RogersJaffer A AjaniPublished in: Expert review of anticancer therapy (2022)
Nivolumab in combination with chemotherapy appears well tolerated, with only a small number of patients reporting severe toxicity; therefore, it may be possible to add additional biological agents to improve outcomes. A number of 'nivolumab plus other agents' is currently being investigated, and we anticipate continued advancement in GEC management in the coming years.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- locally advanced
- small cell lung cancer
- chronic kidney disease
- prognostic factors
- early onset
- radiation therapy
- adipose tissue
- young adults
- high resolution
- skeletal muscle
- atomic force microscopy
- single molecule
- drug induced
- glycemic control